CDK2/4/6 Inhibitor RGT-419B in HR-Positive, HER2-Negative Metastatic Breast Cancer
Condition: Breast Cancer
Sponsor: Regor Pharmaceuticals, Inc.
Full Title
RGT-419B_01-101: First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer
Eligibility
HR-Positive, HER2-Negative metastatic breast cancer that has progressed after treatment with at least one prior hormonal therapy and one or two prior lines of treatment with a CDK4/6 inhibitor.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
